S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:CDXS

Codexis (CDXS) Stock Forecast, Price & News

$2.21
-0.14 (-5.96%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.21
$2.40
50-Day Range
$2.21
$4.43
52-Week Range
$2.20
$13.03
Volume
2.49 million shs
Average Volume
721,751 shs
Market Capitalization
$147.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Codexis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
601.4% Upside
$15.50 Price Target
Short Interest
Bearish
6.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$462,673 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.91) to ($0.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

525th out of 1,006 stocks

Industrial Organic Chemicals Industry

10th out of 20 stocks


CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

Codexis (NASDAQ:CDXS) Lifted to "Hold" at StockNews.com
Major Financial Crisis Could Hit America
Something strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs?
Codexis (NASDAQ:CDXS) Cut to Neutral at HC Wainwright
Codexis (NASDAQ:CDXS) Price Target Cut to $9.00
Codexis (NASDAQ:CDXS) Downgraded to "Sell" at StockNews.com
Major Financial Crisis Could Hit America
Something strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs?
Piper Sandler Keeps Their Buy Rating on Codexis (CDXS)
Codexis (CDXS) to Release Earnings on Thursday
Q4 2022 Codexis Inc Earnings Call
Codexis Announces New Employment Inducement Grants
15 Worst Stock Picks of Cathie Wood in 2022
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
5/04/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+601.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-33,590,000.00
Pretax Margin
-40.93%

Debt

Sales & Book Value

Annual Sales
$116.23 million
Book Value
$1.89 per share

Miscellaneous

Free Float
62,094,000
Market Cap
$147.56 million
Optionable
Optionable
Beta
1.65

Key Executives

  • Stephen George Dilly
    President, CEO & Independent Director
  • Karl A. Schoene
    Senior Vice President-Development & Operations
  • Kevin Norrett
    Chief Operating Officer
  • Sriram Ryali
    Chief Financial & Accounting Officer
  • Stefan Lutz
    Senior Vice President-Research













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2023?

3 analysts have issued 1 year price targets for Codexis' stock. Their CDXS share price forecasts range from $9.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 601.4% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the beginning of 2023. Since then, CDXS stock has decreased by 52.6% and is now trading at $2.21.
View the best growth stocks for 2023 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.05. The biotechnology company earned $12.98 million during the quarter, compared to the consensus estimate of $14.09 million. Codexis had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 32.75%. The company's revenue was down 63.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.13) earnings per share.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$68.00 million, compared to the consensus revenue estimate of $74.57 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.26%), BlackRock Inc. (9.06%), ARK Investment Management LLC (6.51%), Telemark Asset Management LLC (3.84%), State Street Corp (2.58%) and FMR LLC (2.45%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Patrick Y Yang and Stephen George Dilly.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $2.21.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $147.56 million and generates $116.23 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -